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Abstract 
Background: The estrogen‑induced gene 121 (EIG121) has been associated with breast and endometrial cancers, 
but its mechanism of action remains unknown. In a genome‑wide search for tandem repeats, we found that EIG121 
contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expres‑
sion. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk.
Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using 
DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they 
were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable 
with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically 
significant association was identified between the length of this STR and the risk of developing breast or endometrial 
cancer or age at diagnosis.
Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with 
the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the 
regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its 
association with disease recurrence or overall survival remains to be determined.
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Findings
The recent emphasis on high-throughput assays in the 
search to find genetic variants responsible for familial 
cancer risk has failed to account for a significant propor-
tion of cases. Instead, the use of genome-wide associa-
tion studies and next-generation sequencing has revealed 
variants that account for a small portion of heritability 
and has now resulted in the phrase “missing heritabil-
ity” to explain that which remains unaccounted for [1, 
2]. Another form of genetic variation that has been over-
looked, largely due to their inability to be analysed on a 
large scale, is that of variable tandem repeats (TRs) which 
are common throughout the human genome and highly 
mutable [2]. TRs may be drivers of phenotypic variation 
as they are known to be the cause of several neurological 
disorders and are associated with complex diseases such 
as diabetes and cancer [3].
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In a recent study we identified short tandem repeats 
(STRs) in the upstream regulatory region of genes that 
are candidates for conferring cancer risk [4]. One such 
STR is a dinucleotide AG repeat upstream of the estro-
gen-induced gene, EIG121 (also known as KIAA1324). In 
endometrial cancer cases, EIG121 is highly induced by 
estrogen in the endometrium and differentially expressed 
in endometrial cancer types [5, 6]. Studies suggest that 
EIG121, a transmembrane protein, has an important cel-
lular function, as it is highly conserved across species 
and confers survival upon cells that have been starved 
of nutrients or exposed to cytotoxic chemotherapeutics 
[7]. Our analysis from publicly-available datasets, using 
the Oncomine™ Platform (http://www.oncomine.com), 
shows EIG121 to be over-expressed in breast cancer 
compared to other cancer types (Additional file 1: Table 
S1; [8]) and compared to normal breast tissue (Additional 
file 2: Table S2; [9, 10]).
Breast and endometrial cancers are estrogen-driven 
malignancies, and in both diseases, higher expression of 
estrogen-induced genes is associated with tumours that 
tend to be low-grade and less aggressive [5, 11] suggesting 
involvement of these genes in cancer risk and/or develop-
ment. As EIG121 has already been associated with estro-
gen levels and cancer, we analysed the variability of this 
newly identified STR in a series of breast and endome-
trial cancer cases and in a healthy control population to 
determine if there was any association between its length 
and the risk of developing these estrogen-driven cancers.
This study included 223 breast cancer cases, 204 endo-
metrial cancer cases and 220 healthy controls from whom 
blood-derived genomic DNA had been collected for pre-
vious studies in Newcastle, New South Wales (NSW), 
Australia [12–14]. Study participant demographics are 
shown in Table  1. All participants provided written 
informed consent for the samples to be used for research.
The STR (a dinucleotide AG repeat) situated 518  bp 
upstream of the transcription start site for EIG121 was 
genotyped by polymerase chain reaction (PCR) and 
fragment analysis using forward (5′-aggctaatccaggaga 
atctcttg-3′) and reverse (5′-aggctaatccaggagaatctcttg-3′) 
primers designed to amplify a 232  bp length fragment. 
PCR was performed with Platinum Taq DNA Polymer-
ase High Fidelity (Invitrogen), an annealing temperature 
of 61 °C and 1.5 mM MgSO4. Fragment analysis was con-
ducted on the ABI3730 DNA Analyzer (Applied Biosys-
tems (AB)) after denaturation in the presence of HiDi 
Formamide (AB) and GeneScan 600 LIZ Size Standard 
(AB). The resulting electropherograms were analysed 
using Peak Scanner v1.0 software (AB). Sanger sequenc-
ing [12] on at least 10 % of each sample cohort, using the 
same primer sequences as described above, confirmed 
STR lengths. A line of best fit was generated to correct 
lengths obtained from fragment analysis as described by 
Pasqualotto and co-workers [15].
Statistical analyses were performed using the Stata 11.1 
software package (StataCorp LP, College Station, TX, 
USA) and involved non-parametric Mann–Whitney U 
tests, Cox proportional hazard regression, Pearson’s Chi 
squared and Fisher’s exact tests. The significance levels of 
all tests were set at p value  <  0.05 (two-sided) and cor-
rected for multiple comparisons using the Bonferroni 
method.
Based on genotyping results, the AG repeat in the 
upstream regulatory region of EIG121 was highly vari-
able, and showed a bimodal distribution of lengths with 
sizes ranging from 27 to 72 copies across all three cohorts 
(Fig. 1). The mean values for number of copies of the AG 
Table 1 Demographic characteristics of  the participants 
used in this study









Sex All female All female All female
Age (at ascertainment; in years)
 Range N/A 40–92 67–86
 Median 68 73
 Mean (SD) 67.9 (9.5) 73.4 (4.6)
Age (at diagnosis; in years)
 Range 22–57 37–86 N/A
 Median 41 63.5
 Mean (SD) 39.8 (7.3) 63.2 (9.0)
BMI (in kg/m2)a
 Range N/A 16.9–66.6 17.4–47.1
 Median 30.0 27.9
 Mean (SD) 31.3 (7.8) 28.5 (5.3)
 Underweight 
(BMI < 18.5)
n = 1 n = 1
 Normal 
(18.5 ≤ BMI < 25)
n = 37 n = 58
 Overweight 
(25 ≤ BMI < 30)
n = 56 n = 91
 Obese (BMI ≥ 30) n = 94 n = 70
 Not specified n = 16 n = 0
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motif were 37.14, 38.34 and 37.55 for the breast cancer, 
endometrial cancer and healthy control cohorts respec-
tively and the median was 35 for all three cohorts.
A non-parametric Mann–Whitney U test was used 
to test for any association between STR lengths, using 
both allele lengths for each individual, and cancer types. 
This demonstrated a lack of association between STR 
length and breast and endometrial cancers when com-
pared to healthy controls (Table 2). To test if there was 
any association between STR lengths and age at diagno-
sis of the cancers, Cox proportional hazard regression 
was performed. This showed no association between 
STR length and age at diagnosis for breast and endo-
metrial cancers, including when BMI was taken into 
account for endometrial cancer (Table 2). BMI data was 
not available for the breast cancer cohort. When allelic 
(short (S) vs long (L)) and genotypic (SS, SL and LL) 
analyses were performed, using a threshold of 50 cop-
ies for calling short and long alleles, there were no sta-
tistically significant associations for either cancer type 
(Table  2). In the breast cancer cohort, resulting p val-
ues for the allelic and genotypic analyses (p = 0.185 and 
p = 0.102, respectively; Table 2) are inclined towards a 
weak association between STR length and breast can-
cer risk. Further analysis of larger sample sizes or breast 
cancer subtypes would be required to confirm any pos-
sible association.
In conclusion, the AG dinucleotide repeat in the 
upstream regulatory region of EIG121 is a highly poly-
morphic STR, making it a variable genetic element with 
the potential to influence the expression of EIG121 
and subsequently impact disease risk and/or severity. 
No statistically significant association was identified 
between the length of this dinucleotide repeat and the 
age at diagnosis or risk of developing breast or endo-
metrial cancer in the cohorts analysed. Hence, while 
this STR in the regulatory region of EIG121 is highly 
polymorphic, it is unlikely to be associated with the 
risk of developing breast or endometrial cancer. We 
cannot exclude its involvement in recurrence or overall 
survival as this information was not available for this 
study.
Fig. 1 Histogram showing the bimodal distribution of EIG121 STR 
lengths across all three cohorts (breast cancer, endometrial cancer 
and healthy control samples)
Table 2 Hazard ratios (HR), 95 % confidence intervals (CI) and p values for breast and endometrial cancer analysis in rela-
tion to EIG121 STR lengths
Category Statistical test Breast cancer Endometrial cancer
HR (95 % CI) p value HR (95 % CI) p value
Both allele lengths with cancer risk Mann–Whitney U test N/A 0.985 N/A 0.262
Both allele lengths with age at diagnosis Cox proportional hazard regression 0.994 (0.981–1.007) 0.343 1.006 (0.995–1.017) 0.304
Both allele lengths with age at diagnosis  
(BMI considered)
Cox proportional hazard regression N/A N/A 1.003 (0.992–1.015) 0.572
Allelic analysis (S/L) Pearson’s Chi squared test N/A 0.185 N/A 0.393
Genotypic analysis (SS/SL/LL) Fisher’s exact test N/A 0.102 N/A 0.545
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Additional file 1: Table S1. Statistics from analysis of the expression of 
EIG121 (KIAA1324) from Oncomine™ Platform comparisons in multi‑cancer 
datasets (http://www.oncomine.com). The values shown refer to over‑
expression of EIG121 in breast cancer cases relative to other cancer types. 
The total number of samples, n, in each dataset are shown.
Additional file 2: Table S2. Statistics from analysis of the expression of 
EIG121 (KIAA1324) from Oncomine™ Platform comparisons of breast can‑
cer versus normal breast samples (http://www.oncomine.com). The values 
shown refer to over‑expression of EIG121 in breast cancer cases compared 
to normal breast. The number (n) of breast cancer cases and normal breast 
samples are shown for each dataset.
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